Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers
Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This study is a Phase I/IIa, multi-center, open-label study of BR1733 with a dose escalation
part followed by a dose expansion part in adult subjects with advanced cancers.
This treatment to characterize the safety, tolerability, PK, PD and preliminary antitumor
activity.
The study treatment will be administered until the subject experiences unacceptable toxicity,
progressive disease, and/or has treatment discontinued at the discretion of the Investigator
or the subject, or due to withdrawal of consent.